Analyst Conference Summary

biotechnology

conference date: August 4, 2026 @ 1:30 PM Pacific Time
for quarter ending: June 30, 2026 (second quarter, Q2)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was $ million, down % sequentially from $208 million, and up % from $ million year-earlier.

Net Income was negative $ million, up sequentially from negative $2 million, and up from negative $ million year-earlier.

EPS (Earnings per Share), diluted, were negative $, up sequentially from negative $0.04, and up from negative $ year-earlier.

Guidance:

Conference Highlights:

Jack Khattar, President and CEO, said ""

Onapgo resumed new patient initiations in February 2026. Onapgo for Parkinson's disease was launched in April 2025. Demand was greater than expected, so supply was inadequate. Worked to increase the supply and by end of March had reached a new high point for prescriptions.

SPN-817 is a novel AChE inhibitor for epilepsy. A Phase 2b trial is ongoing.

SPN-820 Phase 2b trial for major depressive disorder is ongoing.

SPN-443 completed a Phase 1 study of two oral formulations. ADHD was selected as the lead indication. A Phase 1 trial should start in 2H 2026.

Non-GAAP net operating income was $ million, down from sequentially from $28.7 million, and up y/y from $ million.

Cash and equivalents ended at $ million, up sequentially from $384 million. No debt.

Total expenses were $ million, consisting of: cost of good sold $ million, R&D $ million, SG&A $ million, amortization $ million, contingent consideration loss $ million. Leaving operating earnings of negative $ million. Interest and other income $ million. Income tax benefit $ million.

Q&A (selective summary):

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: